



an Open Access Journal by MDPI

## Diagnosis, Pathogenesis, and Treatment of Atrial Fibrillation

Guest Editor:

### Dr. Kazuyoshi Suenari

Department of Cardiology,  
Hiroshima City Hiroshima  
Citizens Hospital, Hiroshima,  
Japan

Deadline for manuscript  
submissions:

**15 July 2024**

### Message from the Guest Editor

Since atrial fibrillation (AF) is a major cause of cerebral infarction and heart failure, and the prevalence of AF increases with age, its prompt diagnosis and treatment are urgent tasks in this aging society. The management of AF remains challenging despite significant progress in understanding its underlying mechanisms. Considerable progress has been made over the past 20 years in the treatment of AF. Long-term sinus rhythm maintenance rates, although improved compared to the past, have not been as good as for the other supraventricular tachyarrhythmias. This may be because there are still many unknowns regarding the persistent mechanisms of AF, identification of non-pulmonary vein triggers, the need for therapeutic intervention in the right as well as the left atrium, and the involvement of genetic predisposition.

We invite scholars in this complex field to submit original articles and review articles, including studies and opinions on the pathogenesis of AF, techniques to analyze its pathogenesis, the status of disease-modifying therapies to prevent AF progression and improve outcomes, new promising therapeutic concepts, and prospects in the field of atrial arrhythmias.



[mdpi.com/si/196605](https://mdpi.com/si/196605)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)